Article
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2006
Robles Ana I, Wright Mollie H, Gandhi Bheru, Feis Steven S, Hanigan Christin L, Wiestner Adrian, Varticovski Lyuba
Abstract excerpt
PURPOSE: Loss of p53 function impairs apoptosis induced by DNA-damaging agents used for cancer therapy. Here, we examined the effect of the heat shock protein 90 (HSP90) inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (DMAG) on doxorubicin-induced apoptosis in lymphoma. We aimed to establish the optimal schedule for administration of both drugs in combination and the molecular basis for their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.